Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) (2022)
- Authors:
- USP affiliated authors: ZUARDI, ANTONIO WALDO - FMRP ; GUIMARÃES, FRANCISCO SILVEIRA - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; SANTOS, RAFAEL GUIMARÃES DOS - FMRP ; SOUZA, JOSÉ DIOGO RIBEIRO DE - FMRP ; PACHECO, JÚLIA COZAR - FMRP ; ROSSI, GIORDANO NOVAK - FMRP
- Unidade: FMRP
- DOI: 10.3390/pharmaceutics14122598
- Subjects: CANABINOIDES; INTERAÇÃO DE MEDICAMENTOS; ENSAIO CLÍNICO CONTROLADO RANDOMIZADO; MEDICAMENTO
- Keywords: Cannabidiol; CBD; Safety; Adverse effects; Drug interaction
- Language: Inglês
- Imprenta:
- Source:
- Título: Pharmaceutics
- ISSN: 1999-4923
- Volume/Número/Paginação/Ano: v. 14, art. 2598, p. 1-14, 2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
SOUZA, José Diogo Ribeiro de et al. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics, v. 14, p. 1-14, 2022Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics14122598. Acesso em: 04 ago. 2025. -
APA
Souza, J. D. R. de, Pacheco, J. C., Rossi, G. N., Paulo, B. O. de, Zuardi, A. W., Guimarães, F. S., et al. (2022). Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics, 14, 1-14. doi:10.3390/pharmaceutics14122598 -
NLM
Souza JDR de, Pacheco JC, Rossi GN, Paulo BO de, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA de S, Santos RG dos. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) [Internet]. Pharmaceutics. 2022 ; 14 1-14.[citado 2025 ago. 04 ] Available from: https://doi.org/10.3390/pharmaceutics14122598 -
Vancouver
Souza JDR de, Pacheco JC, Rossi GN, Paulo BO de, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA de S, Santos RG dos. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) [Internet]. Pharmaceutics. 2022 ; 14 1-14.[citado 2025 ago. 04 ] Available from: https://doi.org/10.3390/pharmaceutics14122598 - Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials
- Cannabidiol for the treatment of epilepsy: an overview of possible mechanisms of action and preclinical and human studies
- Cannabidiol for the treatment of drug use disorders
- Cannabidiol as a treatment for mental health outcomes among health care workers during the coronavirus disease pandemic. [Carta]
- Dr. Raphael Mechoulam, cannabis and cannabinoids research pioneer (November 5, 1930-March 9, 2023) and his legacy for Brazilian pharmacology [Editorial]
- Classical hallucinogens as antidepressant drugs [Editorial]: a cautionary approach
- The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials
- Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges
- Possible therapeutic uses of cannabidiol in anxiety disorders and schizophrenia
- Cannabidiol, a cannabis sativa constituent, as an antipsycholic drug
Informações sobre o DOI: 10.3390/pharmaceutics14122598 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003153761.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
